Achieve Life Sciences, INC 8-K filings

Achieve Life Sciences announced a significant private placement and leadership enhancements, while also detailing a delay in its cytisinicline New Drug Application resubmission due to manufacturing observations.

Achieve Life Sciences Inc. announced amendments to its charter to increase authorized shares and reported election results for its board of directors and ratification of its auditor.

Achieve Life Sciences, Inc. announced the appointment of two new directors to its Board, effective May 29, 2026.

Achieve Life Sciences announced a significant private placement of up to $354 million, appointed a new CEO, and provided updates on its cytisinicline development and manufacturing readiness.

Achieve Life Sciences has entered into a $354 million private placement agreement to fund cytisinicline development and commercialization while announcing a CEO transition.

Achieve Life Sciences announced its fourth quarter and full year 2025 financial results, alongside significant progress in cytisinicline's regulatory pathway and commercial readiness, including a new U.S. manufacturing partnership.

Achieve Life Sciences announced its third quarter 2025 financial results and provided updates on its cytisinicline program, including an FDA PDUFA date and a National Priority Voucher for vaping cessation.

Achieve Life Sciences' Chief Medical Officer and President, Dr. Cindy Jacobs, has resigned, transitioning to a consulting role until FDA NDA approval for cytisinicline, with severance and accelerated equity vesting.

Achieve Life Sciences announces the resignation of Dr. Cindy Jacobs as Chief Medical Officer and President, effective October 6, 2025.

Achieve Life Sciences announced its second quarter 2025 financial results, highlighted by the submission of its New Drug Application for cytisinicline to the FDA and a successful $49.3 million public offering.

Achieve Life Sciences, a late-stage specialty pharmaceutical company, has priced an underwritten public offering of common stock and accompanying warrants, aiming to raise approximately $41.3 million in net proceeds to fund the continued advancement of its lead product candidate, cytisinicline.

Achieve Life Sciences, Inc. announced the results of its Annual Meeting of Stockholders, where directors were elected and auditors ratified, but a proposal to increase shares for its non-employee director equity incentive plan was not approved.

Achieve Life Sciences reported its Q1 2025 financial results and reiterated its plan to submit a New Drug Application (NDA) for cytisinicline to the FDA in June 2025.

Achieve Life Sciences reports its year-end 2024 financial results and reiterates its plan to submit a New Drug Application (NDA) for cytisinicline at the end of Q2 2025.

Achieve Life Sciences reports positive safety data from the ORCA-OL trial for cytisinicline, with no unexpected adverse events, and reiterates its plan to submit a New Drug Application (NDA) in Q2 2025.

Achieve Life Sciences has appointed two new directors to its board following the resignation of Dr. Vaughn Himes, effective January 6, 2025.

Achieve Life Sciences has appointed Mark K. Oki as its new Chief Financial Officer, effective December 5, 2024.

Achieve Life Sciences reported its third quarter 2024 financial results, completed enrollment in a key clinical trial, and received Breakthrough Therapy designation from the FDA for its vaping cessation treatment.

Achieve Life Sciences has entered into an agreement with Jefferies LLC to sell up to $50 million of its common stock through an at-the-market offering program.

Achieve Life Sciences has announced the departure of its CEO, John Bencich, and the appointment of Richard Stewart as the new CEO, along with other board and committee changes.

Achieve Life Sciences reported its second quarter 2024 financial results, highlighted by FDA Breakthrough Therapy designation for cytisinicline in vaping cessation and a loan refinancing.

Achieve Life Sciences has entered into a new contingent convertible debt agreement for $10 million, with an additional $10 million potentially available, to refinance its existing debt and support operations.

Achieve Life Sciences has entered into a non-binding term sheet to refinance its existing term loans with Silicon Valley Bank, potentially securing up to $20 million with an extended maturity date.

Achieve Life Sciences held its annual meeting on June 5, 2024, where shareholders elected eight directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's auditor for the fiscal year ending December 31, 2024.

Achieve Life Sciences announced its first quarter 2024 financial results, highlighted by a $60 million capital raise and progress in cytisinicline development.

Achieve Life Sciences reported its 2023 financial results, highlighted by a significant funding round and progress in the development of cytisinicline for smoking cessation.

Achieve Life Sciences has announced a financing deal that could provide up to $124.2 million to support the development of its smoking cessation drug, cytisinicline.